Bringing the Future of Hematology 100X Closer

With their end-to-end digital workflow for PBS, Scopio Labs is transforming hematology cell analysis. Learn how our partnership is enhancing clinical workflows and shaping the future of hematology.
Bringing the Future of Hematology 100X Closer

Partners in Innovation

In this SelectScience interview from AACC 2022, Peter Soltani, Senior VP at Beckman Coulter, and Itai Hayut, co-founder and CEO at Scopio Labs, discuss how Scopio’s AI-powered workflow solution is changing hematology imaging and share their excitement around the new partnership.

The increasing worldwide prevalence of hematological disorders and malignancies is exponentially increasing the required amount of diagnostic testingmaking the importance of early diagnosis and effective treatment initiation more important than ever. Understanding blood cellular morphology adds to the value of a routine blood count and can help to identify hematologic disorders. Traditionally, peripheral blood smear (PBS) analysis has been performed manually. To improve both speed and accuracy, however, we need to lean in to technology – especially as laboratorians and clinicians are already required to do more with fewer people and resources.

Scopio Labs is advancing global hematology diagnostics with their regulatory-cleared digital imaging platforms and Full-Field Peripheral Blood Smear™ (FF-PBS) application, a fully digitized cell morphology platform. FF-PBS allows for high-resolution imaging over the entirety of the clinically-relevant slide – from the monolayer to the feathered edge – for a fully digital image that eliminates the need for manual microscopy. Incorporating AI into the platform saves time and aids in clinical diagnosis by pre-classifying cells prior to expert review.

Digitalization of hematology slides is tranforming cell morphology analysis and changing how scientists work both inside and outside the lab. Because the samples are fully digital, clinicians and lab professionals have the ability to analyze samples from anywhere in their hospital's secure network, supporting more collaboration and faster review.

We’re thrilled to add this ground-breaking technology to our suite of innovative hematology solutions.

Watch interview

“We are excited to partner with Scopio Labs to bring cutting edge digital peripheral blood smear analysis and the use of AI decision support to our customers, continuing our push to innovate and solve everyday problems for the lab.”
Peter Soltani
Senior Vice President & General Manager
Beckman Coulter
1. The Lancet Hematology. (2020). The global burden of hematological diseases. The Lancet Hematology, 7(12), e851. https://doi.org/10.1016/s2352-3026(20)30370-7
Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

A New Powerful Web Search Experience

A New Powerful Web Search Experience

Beckman Coulter is thrilled to introduce a revolutionary new web search experience, empowering you to find information faster, making your searches more productive than ever before.
Bacterial Resistance: Actions from the Core Microbiology Lab

Bacterial Resistance: Actions from the Core Microbiology Lab

Learn from our MicroTeam some “MicroTips” about the critical role of the microbiology laboratory for patients, reporting, and the larger impact to antimicrobial stewardship.
Alzheimer’s disease: Challenges to diagnosis and the emerging treatment landscape

Alzheimer’s disease: Challenges to diagnosis and the emerging treatment landscape

Alzheimer's disease is the most common form of dementia. The prevalence of this debilitating disease is expected to continue to rise in the coming years as the global population ages, making it an increasingly important global public health issue.